Precision OpticsPOCI
Recorded

Precision Optics 2027 Q1 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ1 2027Duration49 minParticipants6

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please note, this event is being recorded. I would now like to turn the conference over to Robert Blum with Lytham Partners. Please go ahead. All right.

Robert BlumManaging Partner

Thank you very much, operator, and thank you to everyone joining the call today. As the operator mentioned, on today's call, we will discuss Precision Optics' first quarter fiscal year 2027 financial results, and it's for the period ended September 30, 2026. With us on the call representing the company today is Dr. Joe Forkey, Precision Optics Chief Executive Officer, and Wayne Coll, the company's Chief Financial Officer. At the conclusion of today's prepared remarks, we will open the call for a question-and-answer session. If you dialed into the call through the traditional teleconference line, as the operator indicated, please press star then one to ask a question. If you are listening through the webcast portal and would like to ask a question, then you can submit your question through the Ask a Question feature in the webcast player.

Robert BlumManaging Partner

Before we begin with prepared remarks, we submit for the record the following statement. Statements made by the management team of Precision Optics during the course of this conference call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies, and are generally preceded by words such as may, future, plan or planned, will or should, expected, anticipates, draft, eventually, or projected.

Robert BlumManaging Partner

Listeners are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risk that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in the company's filings with the Securities and Exchange Commission. All forward-looking statements contained during this conference call speak only as of the date in which they are made and are based on management's assumptions and estimates as of such date. Company does not undertake any obligation to publicly update any forward-looking statements, whether as the result of the receipt of new information, the occurrence of future events, or otherwise. With that said, let me turn the call over to Dr. Joe Forkey, Chief Executive Officer of Precision Optics.

Joe ForkeyCEO

Joe, please proceed. Thank you, Robert, and thank you all for joining our call today.

Joe ForkeyCEO

Revenue in our first quarter of fiscal 2027 was $8.2 million. That was down from the record $8.8 million in the previous quarter, but up 22% from a year ago. As we have discussed on previous calls, we expected a slowdown in orders from our existing satellite customer, and we are seeing that in effect. We have positive news regarding that customer that I will elaborate on in just a minute. Even with fewer satellite sub-assembly shipments than in the previous quarter, we still sustained much of the increase in production we achieved last year. Manufacturing overall came in ahead of our internal expectations, including a stronger contribution from our micro-optics lab. We also did better than we expected on adjusted EBITDA.

Joe ForkeyCEO

We had a loss of approximately $200,000 compared to a loss of $1.2 million a year ago. Higher production volumes and the work our COO, Joe Traut, and his team have done to improve manufacturing efficiency both contributed to that improvement. The reduction in satellite sub-assembly shipments impacted the first quarter and will further impact the second quarter. As we reported just a couple weeks ago, this customer has now placed the next follow-on order much sooner than previously expected. We still anticipate the slowdown in satellite sub-assembly shipments to significantly affect our December quarter, but we expect revenue on this program to recover in Q3 and Q4. In the meantime, we will continue to grow with other customers so that the overall top line should be meaningfully higher when our satellite customer returns to its normal demand.

Joe ForkeyCEO

In the first quarter, we started production on a urology product. In just this month, we restarted production of an endoscope used in robotic surgery. These are the first two of four development programs we expect will transfer to production this fiscal year and contribute to production revenue in the second half. Most importantly, as we look out beyond Q2 to the end of this fiscal year and the beginning of fiscal 2028, we expect quarterly revenue to again reach new record highs. These revenue levels will be supported by a base of existing satellite sub-assembly and single-use endoscope production, along with steady Ross Optical revenue, augmented by a recovery in our micro-optics defense business, by the four programs transitioning to production, and by an increase in our product development engineering work supported by recent updates in our sales organization.

Joe ForkeyCEO

In addition, the opportunity represented by our new second satellite sub-assembly program has the potential to further drive growth to even higher levels by the middle of fiscal 2028. On our call today, I will focus my comments primarily on three topics. First, the business update, including the major programs behind the first quarter results, along with those transitioning to production. Second, a brief overview of updates in our sales and marketing activities and some broad market observations. Finally, I will put those developments in the context of our outlook for fiscal 2027. As we discussed on our last call, our satellite customer has pulled back on demand for our optical communication sub-assembly. First quarter revenue for this program was $2.3 million, a quarter-over-quarter decrease of 39%.

Joe ForkeyCEO

With projected revenue of only $1.2 million, we expect the second quarter will be the minimum of the dip caused by this customer's pullback. Our customer has now issued a follow-on order and shared with us their downstream build and launch plans, which support anticipated production levels of approximately $2 million for each of Q3 and Q4. An update to the product design is anticipated for fiscal 2028, but with transition planning already begun, we expect quarterly production and revenue levels to remain similar or slightly higher in fiscal 2028. We have also begun discussions for POC to take over production of additional optical sub-assemblies for this program. While these discussions are still very early stage, they could represent a substantial increase in revenue from this customer if they are successful.

Joe ForkeyCEO

In late September, we received a follow-on engineering order from our second satellite communications customer, a U.S.-based technology company developing a new satellite communications constellation. Over the last two months, POC's technical team, working closely with our customer's team, has completed a first-round prototype design in record time, on schedule, and within budget. Our customer has expressed complete satisfaction with this work. This program continues to move forward with urgency, driven by our customer's desire to get through prototype builds, design updates, and production launch as quickly as possible. Our customer has repeatedly expressed a need to ensure that the final design be well-aligned with POC's manufacturing capabilities, supporting their expressed intent to have POC manufacture the product once development is complete. This customer now anticipates production to begin about a year from now, in the fourth quarter of calendar 2028.

Joe ForkeyCEO

Turning to single-use medical devices, our cystoscope program generated approximately $1.8 million in production revenue in the quarter, driven by ongoing improvements in throughput and yield. Over the last several quarters, we have reached a point where we can plan and forecast performance of this production line with considerably more confidence than we could a year ago, another great indicator of the maturity of our production operations. On our single-use ophthalmic program, we generated $581,000 of revenue in Q1, as shipments increased under the existing $3.5 million order. Based on the experience we gained with the single-use cystoscope product, we have been able to bring the single-use ophthalmic line up to volume more quickly and efficiently, achieving better throughput, yields, and margins earlier in the life of the program.

Joe ForkeyCEO

As this production line continues to mature, we expect revenue to increase, particularly in the second half of this fiscal year. In the first quarter, we started production of a CMOS-based optical sub-assembly for a ureteroscope that has been in our product development pipeline for a few years. Just a couple weeks ago, we restarted production of a rigid endoscope with an articulating tip used for robotic surgery after roughly two years of design and manufacturing process updates. We expect this program to begin contributing production revenue in the second quarter. These are two of the programs we have been anticipating would transition from product development to production this year. We have two additional programs that we expect to move into production over the next six to nine months, a micro endoscope for an arthroscopic application and a high-end borescope for aerospace applications.

Joe ForkeyCEO

For all three of these programs transferring to production, initial volumes will be typically modest, and we expect them to build over time. By the end of this fiscal year, we expect these programs combined will be at an annual run rate of $1.5 million-$2 million per year, and that they will eventually grow to contribute approximately $5 million-$6 million annually. In our micro-optics lab, we started production during the second quarter on the $1.3 million follow-on order that we discussed on our last call for the sub-assembly used in a defense application. We have manufactured this product for many years, and therefore expect good margins and predictability. With the introduction of additional sales resources, we are beginning to see additional programs come into the micro-optics lab pipeline.

Joe ForkeyCEO

Finally, revenue from our Ross Optical division for the first quarter was $1.3 million, down from the previous quarter by 10%, but up year-over-year by 26%. We anticipate Ross revenue to continue at this level for the remainder of fiscal 2027. On our last few calls, we have highlighted the need to reinvigorate our product development pipeline. This part of our business is a profit center itself, but more importantly, it develops the programs that ultimately feed our production business, which drives long-term growth. As we discussed on our last call, Peter Thier joined us about two months ago as Senior Vice President of Sales and Marketing. He is moving aggressively to improve and augment our sales process and team, and I'm confident that with his leadership, we will quickly improve our product development pipeline.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day